Zobrazeno 1 - 10
of 83
pro vyhledávání: '"Grönke, Lars"'
Autor:
Calverley, Peter M A, Anzueto, Antonio R, Carter, Kerstine, Grönke, Lars, Hallmann, Christoph, Jenkins, Christine, Wedzicha, Jadwiga, Rabe, Klaus F
Publikováno v:
In The Lancet Respiratory Medicine May 2018 6(5):337-344
Autor:
Ichinose, Masakazu, Kato, Motokazu, Takizawa, Ayako, Sakamoto, Wataru, Grönke, Lars, Tetzlaff, Kay, Fukuchi, Yoshinosuke
Publikováno v:
In Respiratory Investigation March 2017 55(2):121-129
Autor:
Singh, Dave, Ferguson, Gary T., Bolitschek, Josef, Grönke, Lars, Hallmann, Christoph, Bennett, Nathan, Abrahams, Roger, Schmidt, Olaf, Bjermer, Leif
Publikováno v:
In Respiratory Medicine October 2015 109(10):1312-1319
Autor:
Beeh, Kai-Michael, Westerman, Jan, Kirsten, Anne-Marie, Hébert, Jacques, Grönke, Lars, Hamilton, Alan, Tetzlaff, Kay, Derom, Eric
Publikováno v:
In Pulmonary Pharmacology & Therapeutics June 2015 32:53-59
Autor:
Richter, Kai, Grönke, Lars, Janicki, Stanislawa, Maus, Joachim, Jörres, Rudolf A., Magnussen, Helgo
Publikováno v:
In Pulmonary Pharmacology & Therapeutics 2008 21(1):61-66
Autor:
Rabe, Klaus F., Halpin, David M. G., Han, MeiLan K., Miravitlles, Marc, Singh, Dave, Grönke, Lars, Voß, Florian, Martinez, Fernando J.
Additional file 1: Supplementary Table 1. Patients with FEV1 decline or SGRQ increase 6, 12, 18, 24, 30, 36, 42, and 48 months after the first confirmed FEV1 decline or SGRQ increase by GOLD 2, GOLD 3, and GOLD 4. Supplementary Table 2. Patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d40474fc0d6955676cd697d02db0df4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Ferguson, Gary T, Karpel, Jill P, Clerisme-Beaty, Emmanuelle, Grönke, Lars, Voß, Florian, Buhl, Roland
Publikováno v:
International Journal of Chronic Obstructive Pulmonary Disease
Background Increasing age is associated with poor prognosis in patients with COPD. Objective This analysis from the replicate Phase III OTEMTO® and TONADO® studies examined the efficacy and safety of tiotropium, a long-acting anticholinergic, combi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5227183d83f2976d6443cf6dcaca0f43
http://europepmc.org/articles/PMC5098524
http://europepmc.org/articles/PMC5098524
Autor:
Maltais, François, Buhl, R., Koch, A., Amatto, Valeria, Reid, Jim, Grönke, Lars, Bothner, Ulrich, Voß, Florian, McGarvey, Lorcan, Ferguson, Gary T
Publikováno v:
Maltais, F, Buhl, R, Koch, A, Amatto, V, Reid, J, Grönke, L, Bothner, U, Voß, F, McGarvey, L & Ferguson, G T 2018, ' Beta-blockers in Chronic Obstructive Pulmonary Disease: a Cohort Study from the TONADO Research Programme ', Chest, vol. 153, no. 6, pp. 1315-1325 . https://doi.org/10.1016/j.chest.2018.01.008
BACKGROUND: Cardiovascular disease is a frequent co-morbidity in patients with chronic obstructive pulmonary disease (COPD). Many clinicians, particularly pulmonologists, are reluctant to use β-adrenoceptor blocking agents (β-blockers) in patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2607::8e15cda0ea7755a093d9c408878c7d85
https://pure.qub.ac.uk/en/publications/betablockers-in-chronic-obstructive-pulmonary-disease-a-cohort-study-from-the-tonado-research-programme(0b1e2c74-80bf-4f6b-8662-ca87ec4ce2ea).html
https://pure.qub.ac.uk/en/publications/betablockers-in-chronic-obstructive-pulmonary-disease-a-cohort-study-from-the-tonado-research-programme(0b1e2c74-80bf-4f6b-8662-ca87ec4ce2ea).html
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.